NEWS
Our Latest News
ARCHIMED MedTech sells orthopedic implants maker Citieffe to Poly Medicure, a leading global manufacturer of medical devices
Citieffe was the last investment in ARCHIMED’s MED I fund, now fully liquidated after generating 7.2 times investors’ money, or a 59 percent annual return over 11 years – the best performance of any 2014-vintage buyout fund.
ARCHIMED acquires cell line development pioneer ExcellGene to accelerate expansion into biosimilars and high-performance transfection solutions
September
25,
2025
ARCHIMED acquires generative AI Diagnostics player Arkstone to support fight against infectious disease
August
1,
2025
ARCHIMED’s MED II sells DIESSE, returning 4.6x to shareholders
January
27,
2025
368